OBJECTIVES~Primary i. To determine if patients' VAS pain while walking is different at 6 weeks post-injection in patients who receive a single injection of methylprednisolone acetate (MPA) versus patients who receive a single injection of Hylan G-F 20 (Synvisc One™) for treatment of knee OA.~Secondary i. To determine if differences in VAS pain while walking scores exist at 1 and 3 weeks, and 3 and 6 months post injection between MPA and HA patients.~ii. To determine if differences in VAS pain at rest scores exist at 1, 3 and 6 weeks and 3 and 6 months post injection between MPA and HA patients.~iii. To determine if differences in VAS pain with stairs scores exist at 1, 3 and 6 weeks and 3 and 6 months post injection between MPA and HA patients.~iii. To determine if differences in KOOS questionnaire scores exist at 6 weeks, 3 months and 6 months post injection between MPA and HA patients.~iv. To determine if differences in WOMAC questionnaire scores exist at 6 weeks, 3 months, and 6 months post injection between MPA and HA patients.~v. To determine if differences in adverse events exist at 1, 3 and 6 weeks, and 3, and 6 months post injection between MPA and HA patients.~vi. To track the number of patients who receive additional injections after 3 months following their index injection.
Do differences exist between patients who receive a single intra-articular injection of corticosteroid versus patients who receive a single intra-articular injection of hyaluronic acid for the treatment of knee osteoarthritis at 1, 3 and 6 weeks, and 3 and 6 months post injection?